Safety Of The 300 IR and 500 IR Doses Of A House Dust Mite Allergen Extracts Sublingual Tablet In Adults with Allergic Rhinitis
Poster Mar 09, 2015
Hélène Nguyen, Michel Roux, Josiane Cognet-Sicé, Robert K. Zeldin
Rationale: The efficacy of two doses (300IR and 500IR) of house dust mite (HDM) sublingual tablets was demonstrated in a randomized, DBPC study in patients with HDM-associated allergic rhinitis. Here we present the safety of this treatment.
Methods: Adults (18-50 years) with medically confirmed HDM-associated allergic rhinitis for at least one year were randomized to receive 300IR or 500IR HDM tablet or placebo once daily for one year and were followed for the subsequent year. Adverse events (AE) were monitored throughout the study and analyzed descriptively. All patients who received at least one dose of the investigational product were included in the safety set.
Results: 509 patients (300IR=170, 500IR=169, Placebo=170) were randomized and received at least one dose. 88% (300IR), 83% (500IR) and 80% (Placebo) reported at least one AE on treatment (TEAE). The most common TEAEs reported in the active groups were mild or moderate application site reactions i.e., oral pruritus (25-30% of patients), throat irritation (21-24%) and mouth edema (12-17%), which mostly occurred within the first month of treatment. Nine participants experienced serious TEAEs of which 4 were considered drug-related: pharyngeal edema (300IR), eczema (300IR), moderate respiratory distress related to a sublingual edema (500IR), and urticaria (Placebo); all recovered. Forty-two patients (300IR=17, 500IR=20, and Placebo=5) withdrew from the study due to a TEAE, most commonly pharyngeal edema, dyspepsia, nausea and mouth edema.
Conclusions: Treatment with HDM sublingual tablets at doses of 300IR and 500IR was associated with a favorable safety profile. There was no appreciable difference in tolerability between the tested doses.
Characterization of a Type 2 diabetes-associated islet-specific enhancer cluster in STARD10 by genome editing of EndoC-βH1 cellsPoster
Genome-wide association studies (GWAS) have identified more than 100 genetic loci associated with type 2 diabetes. The majority of these are located in the intergenic or intragenic regions suggesting that the implicated variants may alter chromatin conformation. This, in turn, is likely to influence the expression of nearby or more remotely located genes to alter beta cell function. At present, however, detailed molecular and functional analyses are still lacking for most of these variants. We recently analysed one of these loci and mapped five causal variants in an islet-specific enhancer cluster within the STARD10 gene locus. Here, we aimed to understand how these causal variants influence b-cell function by alteration of the chromatin structure of enhancer clusterREAD MORE
Treatment Options for Chronic Parvovirus Viremia in Pediatric Heart Transplant Patients in a Tertiary Care CenterPoster
This abstract discusses three cases of pediatric heart transplant patients who suffered from parvovirus (B19) infection. Of these patients, two ( B & C) responded well to standard intravenous Ig therapy. Patient A however, did not respond to standard treatment and was begun on subcutaneous Ig, which effectively diminished his viral load. Thus, subcutaneous Ig infusions might serve as a second line treatment for transplant patients with parvovirus who do not respond well to the standard approach.READ MORE
T-helper cell phenotype expression in cutaneous lesions of angioimmunoblastic T-cell lymphomaPoster
Angioimmunoblastic T-cell lymphoma (AITL) is a common type of peripheral T-cell lymphoma. AITL can be missed until lymphadenopathy develops in patients initially presenting with skin lesions, as skin biopsy may lack conclusive findings. Our case highlights the extranodal presentation of AITL with cutaneous lesions displaying the TFH phenotype.READ MORE